These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24114627)

  • 1. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.
    Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
    Int J Cancer; 2014 Apr; 134(7):1741-50. PubMed ID: 24114627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women.
    Leal AD; Thompson CA; Wang AH; Vierkant RA; Habermann TM; Ross JA; Mesa RA; Virnig BA; Cerhan JR
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):151-7. PubMed ID: 26564251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study.
    Podoltsev NA; Wang X; Wang R; Hofmann JN; Liao LM; Zeidan AM; Mesa R; Ma X
    Int J Cancer; 2020 Aug; 147(4):948-957. PubMed ID: 31904114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
    Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
    Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
    Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
    BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
    Price GL; Davis KL; Karve S; Pohl G; Walgren RA
    PLoS One; 2014; 9(3):e90299. PubMed ID: 24618579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environmental Factors, Lifestyle Risk Factors, and Host Characteristics Associated With Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review.
    Allahverdi N; Yassin M; Ibrahim M
    Cancer Control; 2021; 28():10732748211046802. PubMed ID: 34645293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
    Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
    BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
    Roaldsnes C; Holst R; Frederiksen H; Ghanima W
    Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study.
    Pedersen KM; Bak M; Sørensen AL; Zwisler AD; Ellervik C; Larsen MK; Hasselbalch HC; Tolstrup JS
    Cancer Med; 2018 Nov; 7(11):5796-5802. PubMed ID: 30318865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms.
    Krečak I; Gverić-Krečak V; Lapić I; Rončević P; Gulin J; Fumić K; Krečak F; Holik H; Duraković N
    Acta Clin Belg; 2021 Feb; 76(1):32-39. PubMed ID: 31455178
    [No Abstract]   [Full Text] [Related]  

  • 15. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA; Smith-Gagen JA
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for meningioma in postmenopausal women: results from the Iowa Women's Health Study.
    Johnson DR; Olson JE; Vierkant RA; Hammack JE; Wang AH; Folsom AR; Virnig BA; Cerhan JR
    Neuro Oncol; 2011 Sep; 13(9):1011-9. PubMed ID: 21750006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada.
    Bankar A; Zhao H; Iqbal J; Coxford R; Cheung MC; Mozessohn L; Earle CC; Gupta V
    Leuk Lymphoma; 2020 Aug; 61(8):1908-1919. PubMed ID: 32323602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
    Lim Y; Lee JO; Bang SM
    J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.